US FDA delays Lilly Alzheimer’s drug decision, calls for advisory panel
The U.S. Food and Drug Administration has delayed its decision on Eli Lilly’s LLY.N experimental treatment for early Alzheimer’s disease and will hold a meeting of ...
Experimental drug works best for Alzheimer’s patients treated as early as possible
An experimental drug from Eli Lilly LLY.N works best if Alzheimer’s patients are treated as early as possible, ideally before they develop symptoms of the brain-wasting disease, researchers ...
Eisai, Biogen get US FDA approval for Alzheimer’s drug, apply for full approval
The U.S. Food and Drug Administration on Friday approved the Alzheimer’s drug lecanemab developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O for patients in the ...
Alzheimer’s drug succeeds in slowing cognitive decline, makers Eisai and Biogen say
Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said their experimental Alzheimer’s drug significantly slowed cognitive and functional decline in a large trial of patients in the early ...
One in 9 over-65s will develop Alzheimer’s of dementia
One in nine people aged over 65 will develop Alzheimer’s or dementia, the deputy head of the non-profit organisation ‘Min Me Lismonis’ (Forget-me-not), Costas Kapitanis said at a news conference ...
Dementia sufferers neglected by the state
A crucial government plan to improve treatment is still being assessed, leaving families and charities to cope as best they can
Worldwide, dementia is viewed as an epidemic, with over 55 ...